IMRN - Immuron CEO Steven Lydeamore to present at H.C. Wainwright

MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25 ^th Annual Global Investment Conference on September 11 ^th .

The webcast to this presentation will be available here at 7am Eastern Daylight Time / 9pm Australian Eastern Standard time on September 11th.

A copy of the presentation being made at the H.C. Wainwright 25th Annual Global Investment Conference is available on the Company’s website.

https://www.immuron.com.au/corporate-presentations/

This release has been authorised by the directors of Immuron Limited.

COM P ANY CON T ACT:

Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

For more information visit: http://www.immuron.com